Hengrui Medicine completes share repurchase program

Jiangsu Hengrui Medicine (SSE:600276) announced the completion of its share repurchase program on May 15, 2025. The company repurchased 12,905,144 shares, representing 0.20% of its total share capital. The repurchase was executed through centralized bidding, with prices ranging from CNY 39.00 to CNY 57.01 per share. The total expenditure for the buyback amounted to CNY 601,267,615.04 (excluding transaction costs), falling within the announced range of CNY 600 million to CNY 1.2 billion. The repurchased shares will be used for the company's employee stock ownership plan.